Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors

Background and purpose:  Checkpoint kinase 2 (CHK2) is activated by DNA damage and can contribute to p53 stabilization, modulating growth arrest and/or apoptosis. We investigated the contribution of CHK2 to oxaliplatin‐mediated toxicity in a colorectal cancer model.

[1]  M. Saif,et al.  Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies. , 2006, Oncology.

[2]  Andrew J. Wilson,et al.  Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells , 2004, British Journal of Cancer.

[3]  P. Johnston,et al.  Characterization of p53 Wild-Type and Null Isogenic Colorectal Cancer Cell Lines Resistant to 5-Fluorouracil, Oxaliplatin, and Irinotecan , 2004, Clinical Cancer Research.

[4]  A. Sancar,et al.  Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. , 2004, Annual review of biochemistry.

[5]  J. Wils.  Adjuvant Treatment of Colon Cancer: Past, Present and Future , 2007, Journal of chemotherapy.

[6]  John N Weinstein,et al.  Chk2 Molecular Interaction Map and Rationale for Chk2 Inhibitors , 2006, Clinical Cancer Research.

[7]  S. Powell,et al.  Chk 2 Phosphorylation of BRCA 1 Regulates DNA Double-Strand Break Repair , 2003 .

[8]  J. Bisi,et al.  PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2 , 2002, Nature Cell Biology.

[9]  J. Weinstein,et al.  Chk 2 Molecular InteractionMap and Rationale for Chk 2 Inhibitors , 2006 .

[10]  A. Paradiso,et al.  The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines , 2003, Cancer Chemotherapy and Pharmacology.

[11]  G. Jayson,et al.  Preclinical Evaluation of the Pharmacodynamic Properties of 2,5-Diaziridinyl-3-Hydroxymethyl-6-Methyl-1,4-Benzoquinone , 2005, Clinical Cancer Research.

[12]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[13]  B. Kaina,et al.  DNA damage-induced cell death by apoptosis. , 2006, Trends in molecular medicine.

[14]  M. Dolan,et al.  Molecular mechanisms of resistance and toxicity associated with platinating agents. , 2007, Cancer treatment reviews.

[15]  M. Meuth,et al.  A mutant allele of MRE11 found in mismatch repair-deficient tumor cells suppresses the cellular response to DNA replication fork stress in a dominant negative manner. , 2008, Molecular biology of the cell.

[16]  Dirk Strumberg,et al.  The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines , 2005, Anti-cancer drugs.

[17]  J. Bartek,et al.  Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. , 2004, DNA repair.

[18]  C. Prives,et al.  Questioning the Role of Checkpoint Kinase 2 in the p53 DNA Damage Response* , 2003, Journal of Biological Chemistry.

[19]  J. Bartek,et al.  Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage , 2003, Nature Cell Biology.

[20]  M. Broggini,et al.  Chk1, but not Chk2 , is Involved in the Cellular Response to DNA Damaging Agents: Differential Activity in Cells Expressing, or not, p53 , 2004, Cell cycle.

[21]  M. Monden,et al.  Role of p 21 waf 1 / cip 1 in effects of oxaliplatin in colorectal cancer cells , 2005 .

[22]  L. Karlsson,et al.  Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. , 2005, Journal of medicinal chemistry.

[23]  F. Ciardiello,et al.  Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases , 2006, Molecular Cancer Therapeutics.

[24]  B. Zhivotovsky,et al.  Caspase-2 function in response to DNA damage. , 2005, Biochemical and biophysical research communications.

[25]  L V Rubinstein,et al.  Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. , 1990, Journal of the National Cancer Institute.

[26]  H B Broughton,et al.  Molecular modeling. , 2020, Current opinion in chemical biology.

[27]  E. Raymond,et al.  Cellular and molecular pharmacology of oxaliplatin. , 2002, Molecular cancer therapeutics.

[28]  W. Steward,et al.  Detection of oxaliplatin-induced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay. , 2006, DNA repair.

[29]  Eric D. Scheeff,et al.  Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. , 1999, Molecular pharmacology.

[30]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[31]  Alessandra Viel,et al.  Human MRE11 is inactivated in mismatch repair‐deficient cancers , 2002, EMBO reports.

[32]  C. Stevens,et al.  Chk2 activates E2F-1 in response to DNA damage , 2003, Nature Cell Biology.

[33]  Jiri Bartek,et al.  Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.

[34]  David E. Williams,et al.  Inhibition of the G2 DNA Damage Checkpoint and of Protein Kinases Chk1 and Chk2 by the Marine Sponge Alkaloid Debromohymenialdisine* , 2001, The Journal of Biological Chemistry.

[35]  D. Green,et al.  Dissecting p53-dependent apoptosis , 2006, Cell Death and Differentiation.

[36]  B. Kaina,et al.  Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling. , 2008, Toxicology and applied pharmacology.

[37]  T. Mak,et al.  Cross-talk between Chk1 and Chk2 in double-mutant thymocytes , 2007, Proceedings of the National Academy of Sciences.

[38]  G. Kroemer,et al.  Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy , 2004, Oncogene.

[39]  D. Stern,et al.  Chk2 Activation and Phosphorylation-Dependent Oligomerization , 2002, Molecular and Cellular Biology.

[40]  J. Misset,et al.  Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. , 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[41]  M. Garrett,et al.  CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin? , 2007, Nature Reviews Cancer.

[42]  Y Taya,et al.  DNA damage‐inducible phosphorylation of p53 at N‐terminal sites including a novel site, Ser20, requires tetramerization , 1999, The EMBO journal.

[43]  B. Vogelstein,et al.  The Chk2 Tumor Suppressor Is Not Required for p53 Responses in Human Cancer Cells* , 2003, Journal of Biological Chemistry.

[44]  Shuang Huang,et al.  ATR-Chk2 Signaling in p53 Activation and DNA Damage Response during Cisplatin-induced Apoptosis* , 2008, Journal of Biological Chemistry.

[45]  Y. Pommier,et al.  Defective Mre11-dependent Activation of Chk2 by Ataxia Telangiectasia Mutated in Colorectal Carcinoma Cells in Response to Replication-dependent DNA Double Strand Breaks* , 2006, Journal of Biological Chemistry.

[46]  Zhihui Feng,et al.  Chk2 Phosphorylation of BRCA1 Regulates DNA Double-Strand Break Repair , 2004, Molecular and Cellular Biology.

[47]  S. Elledge,et al.  DNA damage-induced activation of p53 by the checkpoint kinase Chk2. , 2000, Science.

[48]  M. Cuadrado,et al.  ATM regulates ATR chromatin loading in response to DNA double-strand breaks , 2006, The Journal of experimental medicine.

[49]  T. Halazonetis,et al.  Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. , 2000, Genes & development.

[50]  M. Monden,et al.  Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells , 2005, Molecular Cancer Therapeutics.

[51]  A. Carlin,et al.  Guidelines 2000 for colon and rectal cancer surgery. , 2001, Journal of the National Cancer Institute.

[52]  C. Britten,et al.  G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer , 2008, British Journal of Cancer.